<DOC>
	<DOC>NCT01069289</DOC>
	<brief_summary>The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.</brief_summary>
	<brief_title>Efficacy and Safety Study of Symbicort速 Turbuhaler速 Versus Oxis速 Turbuhaler速 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A current clinical diagnosis of Chronic Obstructive Pulmonary Disease Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years A smoking history of at least 10 pack years History and/or current clinical diagnosis of asthma History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Symbicort</keyword>
	<keyword>Oxis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Efficacy</keyword>
</DOC>